The national law firm of Parker Waichman LLP has filed a lawsuit in U.S. District Court for the Western District of Louisiana against Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly, on behalf of a Louisiana man who developed bladder cancer after using the type 2 diabetes drug Actos.
According to the lawsuit, the plaintiff used Actos between 2006 and 2008 and developed bladder cancer in 2007. The suit claims that Takeda and Eli Lilly knew of the increased risk of users developing bladder cancer when using Actos, however, they did not warn consumers and physicians about this risk.
Just prior to a label change in the United States, Actos was pulled from the market in France in Germany, and health officials in Canada modified the label of the diabetes drug to warn about the increased bladder cancer risks.
The lawsuit seeks damages for severe mental and physical pain, economic loss due to medical expenses and the expenses resulting from a new lifestyle.
Parker Waichman founding partner Jerrold S. Parker has been named to the Plaintiff’s Steering Committee in the Actos multi district litigation consolidated under Judge Rebecca F. Doherty.